Results 181 to 190 of about 13,600,961 (272)

Real‐world outcomes of zavegepant use in a tertiary care setting using the Migraine Treatment Optimization Questionnaire‐5

Headache: The Journal of Head and Face Pain, Volume 66, Issue 10, Page 2410-2419, November/December 2026.
Abstract Objectives/Background The introduction of calcitonin gene‐related peptide antagonists has transformed migraine care. Zavegepant, a third‐generation intranasal gepant, offers a nonoral treatment option for acute migraine. Although clinical trials support its efficacy and safety, real‐world data are limited.
Eric Dunn, Bradley Ong, Harpreet Kaur, Roman Popov, Claire Sonneborn, Aarushi Suneja   +5 more
wiley   +1 more source

Potential therapeutic role of calcitonin gene-related peptide medications for tinnitus. [PDF]

J Chin Med Assoc
Dichter A, Bhatt K, Gutiérrez Pérez ML, Lee EJ, Tawk K, Djalilian HR.   +5 more
europepmc   +1 more source

Early improvements in function with atogepant as assessed by the Activity Impairment in Migraine–Diary: Post hoc analyses of three randomized, phase 3 clinical trials of atogepant for the preventive treatment of migraine

Headache: The Journal of Head and Face Pain, Volume 66, Issue 10, Page 2264-2276, November/December 2026.
Abstract Objective Evaluate early functional improvements with the preventive migraine treatment atogepant using Activity Impairment in Migraine–Diary (AIM‐D) individual and activity limitation items, and complete improvement in AIM‐D Performance of Daily Activities (PDA) and Physical Impairment (PI) domain scores assessed weekly during the first 4 ...
Richard B. Lipton, Pranav Gandhi, Andreas R. Gantenbein, Brett Dabruzzo, Karen Carr, Jonathan Stokes, Molly Duan, Rashmi B. Halker Singh, Hsiangkuo Yuan, Dawn C. Buse   +9 more
wiley   +1 more source

Calcitonin Gene-Related Peptide (CGRP)-Containing Terminals in the Central Amygdala of Mice and Monkeys: Ultrastructural Analysis and Subsynaptic Expression of GluD1. [PDF]

Eur J Neurosci
Choi D, Villalba RM, Dalal K, Paré JF, Dravid SM, Smith Y.   +5 more
europepmc   +1 more source

Orofacial pain disorder or trigeminal autonomic cephalalgia? Insights into pathophysiology and implications in medicine and dentistry

Headache: The Journal of Head and Face Pain, Volume 66, Issue 10, Page 2460-2471, November/December 2026.
Plain Language Summary There are some headache disorders known as trigeminal autonomic cephalalgias (TACs). When these “headaches” are localized in the mid‐face region, they are known as “trigeminal autonomic orofacial pains” (TAOPs), and they can mimic other types of face pains including dental pain, which puts the patient at risk of receiving ...
Marcela Romero‐Reyes, Simon Akerman
wiley   +1 more source

Sex differences in the expression of calcitonin gene-related peptide (CGRP) and its receptor: a review of contradictory and nuanced findings. [PDF]

Neurobiol Pain
Offurum D, Lorsung R, Masri R, Keller A.
europepmc   +1 more source

Distribution and target engagement of peripherally administered fremanezumab in the cerebrospinal fluid of healthy volunteers

Headache: The Journal of Head and Face Pain, Volume 66, Issue 10, Page 2305-2316, November/December 2026.
Abstract Objectives/Background Our objective was to describe the distribution of fremanezumab to the cerebrospinal fluid (CSF) in healthy volunteers, and investigate its engagement and stabilization of its target, calcitonin gene‐related peptide (CGRP). Fremanezumab is a CGRP‐targeting monoclonal antibody approved for migraine prevention.
Jacki Rorabaugh, Edward Hellriegel, Juline Bryson, Ryan Tiver, Hang Zeng, Xiaofeng Lu, Steve Barash, Giulia Ghibellini, Olga Szilagyi, Ignacio Echenique, Andrew H. Ahn, Peter J. Goadsby, Laura Rabinovich‐Guilatt   +12 more
wiley   +1 more source

Headache disorders among Indigenous communities: A scoping review undertaken with knowledge keeper guidance

Headache: The Journal of Head and Face Pain, Volume 66, Issue 10, Page 2472-2488, November/December 2026.
Abstract Objective We performed a scoping review of literature on headache etiology, classification, prevalence, and treatment in Indigenous communities in Canada, the United States, Australia, and New Zealand. Background In the United States, analysis of national prevalence indicates that Indigenous Americans lead all other racial/ethnic groups in ...
Maia Kelly, Candice M. Todd, Ojistoh Kahnawahere Horn, Emily Simmonds, Diane Longboat, Cynthia White, Suvendrini Lena   +6 more
wiley   +1 more source

Preanalytical stability of plasma calcitonin gene-related peptide: clinical and research implications. [PDF]

J Headache Pain
Frank F, Eller MT, Maier S, Janisch L, Labrecque S, Kaltseis K, Messlinger K, Reindl M, Broessner G.   +8 more
europepmc   +1 more source

Efficacy and Safety of Calcitonin Gene-Related Peptide Monoclonal Antibodies for Cluster Headache: A Systematic Review and Frequentist-Bayesian Meta-Analysis

Calcitonin gene-related peptide (CGRP) monoclonal antibodies have transformed migraine prevention, but their efficacy in cluster headache remains ...
yuanlu
core